title: Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
authors.forename: I
authors.initials: I
authors.lastname: Vergote
authors.forename: G J
authors.initials: GJ
authors.lastname: Rustin
authors.forename: E A
authors.initials: EA
authors.lastname: Eisenhauer
authors.forename: G B
authors.initials: GB
authors.lastname: Kristensen
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.forename: M K
authors.initials: MK
authors.lastname: Parmar
authors.forename: M
authors.initials: M
authors.lastname: Friedlander
authors.forename: A
authors.initials: A
authors.lastname: Jakobsen
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D017410:Practice Guidelines as Topic; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen